2024
A pilot cross-sectional study of non-communicable diseases in TB household contacts
Hamada Y, Lugendo A, Ntshiqa T, Kubeka G, Lalashowi J, Mwastaula S, Ntshamane K, Sabi I, Wilson S, Copas A, Velen K, Ntinginya N, Minja L, Abubakar I, Charalambous S, Rangaka M. A pilot cross-sectional study of non-communicable diseases in TB household contacts. IJTLD OPEN 2024, 1: 154-159. PMID: 38988408, PMCID: PMC11231826, DOI: 10.5588/ijtldopen.23.0579.Peer-Reviewed Original ResearchNon-communicable diseasesTB household contactsNon-communicable disease screeningStudy of non-communicable diseasePrevalence of non-communicable diseasesPilot cross-sectional studyContact investigationCross-sectional studyIntegrated screeningHousehold contactsHemoglobin A1cNeighborhood householdsPrevalenceBlood pressureBlood glucoseSouth AfricaAdult contactsScreeningCareNeighborhoodIndividualsA1CDiabetesDiseasePilot
2023
Safety and Glycemic Outcomes During the MiniMedTM Advanced Hybrid Closed-Loop System Pivotal Trial in Children and Adolescents with Type 1 Diabetes
Pihoker C, Shulman D, Forlenza G, Kaiserman K, Sherr J, Thrasher J, Buckingham B, Kipnes M, Bode B, Carlson A, Lee S, Latif K, Liljenquist D, Slover R, Dai Z, Niu F, Shin J, Jonkers R, Roy A, Grosman B, Vella M, Cordero T, McVean J, Rhinehart A, Vigersky R, Bode B, Buckingham B, Carlson A, Casaubon L, Christiansen M, Cordero T, Garg S, Grosman B, Kaiserman K, Kipnes M, Latif K, Lee S, Liljenquist D, Lintereur L, Liu M, McVean J, Parikh N, Peng F, Pihoker C, Philis-Tsimikas A, Pop-Busui R, Reed J, Rhinehart A, Roy A, Sherr J, Shin J, Shulman D, Singh K, Slover R, Thrasher J, Vella M, Vigersky R, Wu D. Safety and Glycemic Outcomes During the MiniMedTM Advanced Hybrid Closed-Loop System Pivotal Trial in Children and Adolescents with Type 1 Diabetes. Diabetes Technology & Therapeutics 2023, 25: 755-764. PMID: 37782145, DOI: 10.1089/dia.2023.0255.Peer-Reviewed Original ResearchConceptsDiabetic ketoacidosisSensor glucosePivotal trialsSevere hypoglycemiaPredictive low glucose managementSingle-arm studySensor-augmented pumpType 1 diabetesEnd of studyMean sensor glucoseEffectiveness endpointTreat populationGlycemic targetsGlucose targetsInvestigational centersPrimary safetyGlycemic outcomesMean TIRA1CType 1Higher TIRStudy periodClosed-loop useCoefficient of variationLower TBR
2022
Assessing Incorporation of Type 1 Diabetes Into Identity: Validation of the Accepting Diabetes and Personal Treatment (ADAPT) Survey in Teens and Young Adults
Commissariat PV, Volkening LK, Weinzimer SA, Dassau E, Laffel LM. Assessing Incorporation of Type 1 Diabetes Into Identity: Validation of the Accepting Diabetes and Personal Treatment (ADAPT) Survey in Teens and Young Adults. Canadian Journal Of Diabetes 2022, 47: 66-72. PMID: 36184368, PMCID: PMC10096441, DOI: 10.1016/j.jcjd.2022.08.007.Peer-Reviewed Original ResearchConceptsYoung adultsTreatment surveyDiabetes device useLess diabetes distressCross-sectional studyType 1 diabetesQuality of lifeImpact of T1DInternal consistencyLower A1CMale sexDiabetes distressExcellent internal consistencyMedical recordsCGM useDiabetes managementT1DHealth outcomesDiabetesType 1Clinical interventionsPsychosocial outcomesBenefit findingA1CAdultsSGLT2i Improves Glycemic Control in Patients With Congenital Severe Insulin Resistance.
Galderisi A, Tamborlane W, Taylor SI, Attia N, Moretti C, Barbetti F. SGLT2i Improves Glycemic Control in Patients With Congenital Severe Insulin Resistance. 2022, 150 PMID: 35652305, DOI: 10.1542/peds.2021-055671.Peer-Reviewed Original ResearchConceptsRabson-Mendenhall syndromeGlycemic controlHemoglobin A1cRenal calcium excretionInsulin-resistant diabetesSevere insulin resistanceCalcium excretionUrinary calciumAntidiabetic treatmentDay doseDose escalationSecond patientFirst patientInsulin levelsInsulin resistanceUrinary excretionSerum glucosePatientsEmpagliflozinMild increaseDapagliflozinΒ-hydroxybutyrateTarget rangeA1CExcretion
2021
Safety and Glycemic Outcomes During the MiniMed™ Advanced Hybrid Closed-Loop System Pivotal Trial in Adolescents and Adults with Type 1 Diabetes
Carlson AL, Sherr JL, Shulman DI, Garg SK, Pop-Busui R, Bode BW, Lilenquist DR, Brazg RL, Kaiserman KB, Kipnes MS, Thrasher JR, Reed JHC, Slover RH, Philis-Tsimikas A, Christiansen M, Grosman B, Roy A, Vella M, Jonkers RAM, Chen X, Shin J, Cordero TL, Lee SW, Rhinehart AS, Vigersky RA. Safety and Glycemic Outcomes During the MiniMed™ Advanced Hybrid Closed-Loop System Pivotal Trial in Adolescents and Adults with Type 1 Diabetes. Diabetes Technology & Therapeutics 2021, 24: 178-189. PMID: 34694909, PMCID: PMC8971997, DOI: 10.1089/dia.2021.0319.Peer-Reviewed Original ResearchConceptsAdvanced hybrid closed-loop systemMulticenter single-arm studyPredictive low glucose managementDiabetic ketoacidosis eventsSingle-arm studySensor-augmented pumpType 1 diabetesWilcoxon signed-rank testStudy phaseKetoacidosis eventsTreat populationHybrid closed-loop systemMean A1CGlycemic targetsGlucose targetsPivotal trialsStudy endpointGlucose managementGlycemic outcomesSigned-rank testAge groupsStudy participantsType 1Safety eventsA1C
2020
PREDICTIVE VALUE OF HEMOGLOBIN A1C FOR SYSTOLIC FUNCTION IN PATIENTS WITH CONGESTIVE HEART FAILURE AND DIABETES MELLITUS: 2D STRAIN STUDY
Shkolnik E, Stolear A, Zarich S. PREDICTIVE VALUE OF HEMOGLOBIN A1C FOR SYSTOLIC FUNCTION IN PATIENTS WITH CONGESTIVE HEART FAILURE AND DIABETES MELLITUS: 2D STRAIN STUDY. Journal Of The American College Of Cardiology 2020, 75: 1589. DOI: 10.1016/s0735-1097(20)32216-6.Peer-Reviewed Original Research
2019
Glucose management for rewards: A randomized trial to improve glucose monitoring and associated self‐management behaviors in adolescents with type 1 diabetes
Wagner JA, Petry NM, Weyman K, Tichy E, Cengiz E, Zajac K, Tamborlane WV. Glucose management for rewards: A randomized trial to improve glucose monitoring and associated self‐management behaviors in adolescents with type 1 diabetes. Pediatric Diabetes 2019, 20: 997-1006. PMID: 31271239, PMCID: PMC6786915, DOI: 10.1111/pedi.12889.Peer-Reviewed Original ResearchConceptsType 1 diabetesWithdrawal of reinforcementImproved metabolic controlProportion of daysGroup differencesSelf-management behaviorsEffect sizeEUC participantsMean A1CUsual careWeek 24Week 12Blood glucoseGlucose managementWeek 6Metabolic controlAge groupsDiabetesGlucose monitoringBaselineSMBGDurable increaseWeeksA1CWithdrawal
2016
- Combination and Pooling of Biomarkers
Zou K, Liu A, Bandos A, Ohno-Machado L, Rockette H. - Combination and Pooling of Biomarkers. 2016, 84-101. DOI: 10.1201/b11031-7.Peer-Reviewed Original Research
2015
Efficacy and implementation of an Internet psychoeducational program for teens with type 1 diabetes
Whittemore R, Liberti LS, Jeon S, Chao A, Minges KE, Murphy K, Grey M. Efficacy and implementation of an Internet psychoeducational program for teens with type 1 diabetes. Pediatric Diabetes 2015, 17: 567-575. PMID: 26611663, PMCID: PMC4882266, DOI: 10.1111/pedi.12338.Peer-Reviewed Original ResearchConceptsType 1 diabetesSecondary outcomesPsychoeducational programQuality of lifePrimary outcomeClinic recordsPreliminary efficacyMixed model analysisHealth outcomesClinical sitesA1CTargeted reminderBehavioral factorsOutcomesTreatment effectsSignificant differencesDiabetesPerceived stressFamily supportDiabetes websitesFrequent remindersPrescribed programEfficacyTeensGroup
2012
The Landmark JDRF Continuous Glucose Monitoring Randomized Trials: a Look Back at the Accumulated Evidence
Ruedy KJ, Tamborlane WV, for the Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. The Landmark JDRF Continuous Glucose Monitoring Randomized Trials: a Look Back at the Accumulated Evidence. Journal Of Cardiovascular Translational Research 2012, 5: 380-387. PMID: 22538483, DOI: 10.1007/s12265-012-9364-9.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultBiomarkersBlood GlucoseBlood Glucose Self-MonitoringChildDiabetes Mellitus, Type 1Equipment DesignEvidence-Based MedicineGlycated HemoglobinHumansHypoglycemiaHypoglycemic AgentsMulticenter Studies as TopicPatient SatisfactionPredictive Value of TestsRandomized Controlled Trials as TopicTime FactorsTreatment OutcomeUnited StatesYoung AdultConceptsContinuous glucose monitorRandomized trialsT1D managementMulticenter randomized trialType 1 diabetesStandard glucose monitoringPrimary studiesComplications TrialSevere hypoglycemiaHemoglobin levelsDiabetes controlBiochemical hypoglycemiaCGM usePatientsGlucose monitoringAccumulated evidenceSecondary studiesReduced exposureTrialsA1CHypoglycemiaGlucose monitorSubjectsDCCTDiabetesAccuracy and Precision of the Axis-Shield Afinion Hemoglobin A1c Measurement Device
Wood JR, Kaminski BM, Kollman C, Beck RW, Hall CA, Yun JP, Cengiz E, Haller MJ, Hassan K, Klingensmith GJ, Tamborlane WV. Accuracy and Precision of the Axis-Shield Afinion Hemoglobin A1c Measurement Device. Journal Of Diabetes Science And Technology 2012, 6: 380-386. PMID: 22538150, PMCID: PMC3380782, DOI: 10.1177/193229681200600224.Peer-Reviewed Original ResearchConceptsNational Glycohemoglobin Standardization ProgramPediatric practice settingsWhole blood samplesBlood samplesHigh-performance liquid chromatographyPractice settingsDCA deviceHigher A1C levelsBoronate affinity methodMeasurement of hemoglobinA1c levelsDiabetes mellitusClinic sitesA1C resultsClinical centersAfinionCapillary bloodPatient samplesCentral laboratoryConsortium sitesA1CImmunoassay methodStandardization ProgramHPLC methodAbsolute difference
2011
Sensor-Augmented Pump Therapy for A1C Reduction (STAR 3) Study Results from the 6-month continuation phase
Bergenstal RM, Tamborlane WV, Ahmann A, Buse JB, Dailey G, Davis SN, Joyce C, Perkins BA, Welsh JB, Willi SM, Wood MA. Sensor-Augmented Pump Therapy for A1C Reduction (STAR 3) Study Results from the 6-month continuation phase. Diabetes Care 2011, 34: 2403-2405. PMID: 21933908, PMCID: PMC3198292, DOI: 10.2337/dc11-1248.Peer-Reviewed Original ResearchUtility of Hemoglobin A1c for Diagnosing Prediabetes and Diabetes in Obese Children and Adolescents
Nowicka P, Santoro N, Liu H, Lartaud D, Shaw MM, Goldberg R, Guandalini C, Savoye M, Rose P, Caprio S. Utility of Hemoglobin A1c for Diagnosing Prediabetes and Diabetes in Obese Children and Adolescents. Diabetes Care 2011, 34: 1306-1311. PMID: 21515842, PMCID: PMC3114343, DOI: 10.2337/dc10-1984.Peer-Reviewed Original ResearchConceptsOral glucose tolerance testType 2 diabetesObese childrenDiabetes categoriesUse of A1CUtility of hemoglobinPrevalence of prediabetesNormal glucose toleranceAmerican Diabetes AssociationGlucose tolerance testDiagnosis of diabetesDiagnostic toolPoor diagnostic toolA1C categoryBaseline A1CMicrovascular complicationsGlucose toleranceDiabetes AssociationPediatric populationTolerance testMultiethnic cohortA1c measurementA1CDiabetesPrediabetes
2010
Refill Adherence to Oral Hypoglycemic Agents and Glycemic Control in Veterans
Kim N, Agostini JV, Justice AC. Refill Adherence to Oral Hypoglycemic Agents and Glycemic Control in Veterans. Annals Of Pharmacotherapy 2010, 44: 800-808. PMID: 20388863, PMCID: PMC3117591, DOI: 10.1345/aph.1m570.Peer-Reviewed Original ResearchConceptsOral hypoglycemic agentsGlycemic controlGoal A1CHypoglycemic agentsBaseline dateInadequate diabetes controlPercent of patientsPoor glycemic controlMain outcome measuresBaseline A1CContinuous refillNonpersistent patientsComorbid hypertensionDiabetes medicationsMedian ageBetter persistenceMedication nonadherenceDiabetes controlDays' supplyOutcome measuresClinical careEligible veteransPatientsA1CMedications
2009
Sustained Benefit of Continuous Glucose Monitoring on A1C, Glucose Profiles, and Hypoglycemia in Adults With Type 1 Diabetes
Bode B, Beck R, Xing D, Gilliam L, Hirsch I, Kollman C, Laffel L, Ruedy K, Tamborlane W, Weinzimer S, Wolpert H. Sustained Benefit of Continuous Glucose Monitoring on A1C, Glucose Profiles, and Hypoglycemia in Adults With Type 1 Diabetes. Diabetes Care 2009, 32: 2047-2049. PMID: 19675193, PMCID: PMC2768224, DOI: 10.2337/dc09-0846.Peer-Reviewed Original ResearchThe Effect of Continuous Glucose Monitoring in Well-Controlled Type 1 Diabetes
Beck R, Hirsch I, Laffel L, Tamborlane W, Bode B, Buckingham B, Chase P, Clemons R, Fiallo-Scharer R, Fox L, Gilliam L, Huang E, Kollman C, Kowalski A, Lawrence J, Lee J, Mauras N, O'Grady M, Ruedy K, Tansey M, Tsalikian E, Weinzimer S, Wilson D, Wolpert H, Wysocki T, Xing D. The Effect of Continuous Glucose Monitoring in Well-Controlled Type 1 Diabetes. Diabetes Care 2009, 32: 1378-1383. PMID: 19429875, PMCID: PMC2713649, DOI: 10.2337/dc09-0108.Peer-Reviewed Original ResearchConceptsType 1 diabetesContinuous glucose monitoringSevere hypoglycemic eventsCGM groupControl groupHypoglycemic eventsGlucose monitoringGlucose levelsSignificant treatment group differencesMain study outcomeManagement of adultsTreatment group differencesMin/dayStandard glucose monitoringMean A1CA1c levelsMedian timeOutcome measuresA1CBiochemical hypoglycemiaMost outcomesType 1Hypoglycemia dataStudy outcomesDiabetes
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply